Pharmacological and non-pharmacological modulation of striatal dopamine release: a meta-analysis of [11C]raclopride PET studies

The dopaminergic system has long been a central focus of functional neuroimaging. Positron emission tomography (PET) with the D2/D3 receptor radioligand [11C]raclopride remains the most widely used method for indirectly quantifying striatal dopamine release in vivo. However, no previous meta-analysis has studied the relative magnitude and regional distribution of dopamine release across different interventions or cognitive interventions overall.

To address this gap, in this meta-analysis of 92 [11C]raclopride PET studies (n = 1640), we compared the magnitude and regional distribution of dopamine release induced by amphetamine, methylphenidate, ketamine, alcohol, and cognitive challenges with and without reward. Amphetamine induced approximately four-fold greater dopamine release than cognitive challenges (10.9 vs. 2.7%, p 0.10). Methylphenidate-induced increases in synaptic dopamine appeared to attenuate with advancing age, whereas cognitive challenges were associated with greater dopamine release in older individuals.

These findings demonstrate that individual pharmacological and cognitive interventions differ markedly in both magnitude and regional pattern of dopamine release. They also suggest that [¹¹C]raclopride PET may have limited sensitivity for distinguishing reward-related from non-reward-related dopamine release. These findings have implications for the design and interpretation of future neuroimaging studies of dopaminergic function in health and disease.

Dopamine is a key neurotransmitter involved in motor control, reward processing, affective regulation, and behavioral reinforcement through distinct neural circuits [1, 2]. Dopaminergic signaling within the nigrostriatal and mesocorticolimbic pathways operates via both tonic and phasic mechanisms [2]. The nigrostriatal pathway, projecting from the substantia nigra to the dorsal striatum, primarily supports motor function, whereas mesocorticolimbic projections from the ventral tegmental area (VTA) to the ventral striatum and prefrontal cortex are central to motivation, reward, and cognition [1].

Dysregulation of these systems is implicated in several neurological and psychiatric disorders, including Parkinson’s disease [3], schizophrenia [4], attention-deficit hyperactivity disorder [5], and addiction [6]. Because endogenous dopamine competes with [11C]raclopride at D2/D3 receptors, increased dopamine release is inferred from reduced binding potential [7]. This approach has enabled the quantification of dopamine release across a range of pharmacological and behavioral interventions.

Psychostimulants such as amphetamine and methylphenidate markedly increase synaptic dopamine and are commonly used to characterize dopaminergic responsivity and to compare clinical populations to healthy controls [8,9,10,11,12]. In parallel, cognitive paradigms have been used to investigate dopamine system dynamics in relation to reward processing and goal-directed behavior [13]. Reward is typically defined as any stimulus that induces subjective pleasure or reinforces behavior [14].